GLP-1 Coverage for Cardiovascular Risk: What Medicare Pays

For years, the biggest barrier to Medicare coverage of GLP-1 drugs was a simple rule: Part D could not pay for medications used only for weight loss. That changed in a meaningful way when the FDA approved semaglutide to reduce the risk of serious cardiovascular events. This single new indication opened a door to coverage for a large group of beneficiaries who could not get these drugs before. Here is who qualifies and how it works.

In 2024, the FDA approved Wegovy (semaglutide) to reduce the risk of cardiovascular death, heart attack, and stroke in adults who have established cardiovascular disease and are living with obesity or overweight. Because this is a recognized medical indication — not weight loss by itself — Medicare Part D plans were then able to cover the drug for patients who meet the criteria. Soon after, the Centers for Medicare & Medicaid Services confirmed that Part D plans may cover anti-obesity medications when they are approved for an additional medically accepted use such as cardiovascular risk reduction. You can read the approved indication on FDA.gov.

Coverage under the cardiovascular indication is not automatic for everyone who wants a GLP-1. In general, your prescriber needs to document that you:

• Are enrolled in a Medicare Part D plan (stand-alone or through Medicare Advantage).
• Have established cardiovascular disease — for example, a prior heart attack or stroke, or diagnosed coronary artery disease.
• Have a qualifying body-mass index consistent with obesity or overweight, as defined in the drug's labeling.
• Are receiving the drug for the FDA-approved cardiovascular purpose, documented in your records.

Source: CMS.gov and FDA.gov. Criteria are illustrative — your plan sets the exact requirements.

Even with a qualifying condition, the drug almost always requires prior authorization. Your prescriber submits documentation of your cardiovascular history and BMI to your Part D plan, which then reviews the request — usually within 72 hours, or 24 hours if expedited. If the plan asks for more information, respond quickly. If it denies the request, you have full appeal rights; see our guide on what to do if your prior authorization is denied.

It is worth emphasizing what this pathway does not do: it does not make GLP-1 drugs covered for weight loss alone. A beneficiary who wants the medication purely to lose weight, without the cardiovascular diagnosis, generally still will not qualify under Part D. The expansion is specifically about reducing cardiovascular risk in people who already have heart disease.

Once approved, you pay your plan's copay or coinsurance rather than the full cash price, which often tops $1,000 a month. Covered Part D drugs are also subject to the annual out-of-pocket cap created by the Inflation Reduction Act, so your yearly spending on covered medications is limited. Estimate your share with our cost calculator, and confirm the current cap on CMS.gov. If you are not sure whether your heart history qualifies, talk with your prescriber — they can tell you whether your records support a request under this indication.